The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Some medtech stocks did decline in 2018, but many more increased in value.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Since becoming a pure-play health tech group Philips has been buying like crazy. Might Siemens Healthineers and GE Healthcare join in?
In a quiet year for medical devices a couple of studies are still worth watching.
Big cap medtech is hiring, largely thanks to organic growth.